

## Genetic surveillance of *Plasmodium falciparum* reveals rapid population changes following first-line treatment policy revisions in the Greater Mekong Subregion

Tess D Verschuuren<sup>1</sup>, Varanya Wasakul<sup>1</sup>, Nguyen Thuy-Nhien<sup>2</sup>, Ethan Booth<sup>1</sup>, Huynh Hong Quang<sup>3</sup>, Ngo Duc Thang<sup>4</sup>, Keoubouphaphone Chindavongsa<sup>5</sup>, Siv Sovannaroeth<sup>6</sup>, Virasak Banouvong<sup>5</sup>, Viengphone Sengsavath<sup>5</sup>, Mayfong Mayxay<sup>7,8,9</sup>, Nguyen Thi Kim Tuyen<sup>2</sup>, Vo Ngoc Lam Phuong<sup>2</sup>, Pham Duc Trung<sup>2</sup>, Sónia Gonçalves<sup>10</sup>, Soun Chen<sup>6</sup>, Sonexay Phalivong<sup>7</sup>, Saiamphone Xayvanghang<sup>7</sup>, Supaporn Mahaphontrakoon<sup>1</sup>, Richard D Pearson<sup>10</sup>, Paul N Newton<sup>7,9</sup>, Richard J Maude<sup>1,9,11</sup>, Elizabeth A Ashley<sup>7,9</sup>, Cristina V Ariani<sup>10</sup>, Victoria J Simpson<sup>10</sup>, Nicholas P Day<sup>1,9</sup>, Arjen M Dondorp<sup>1,9</sup>, Olivo Miotto<sup>1,9</sup>

<sup>1</sup>Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

<sup>2</sup>Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam

<sup>3</sup>Institute of Malariology, Parasitology and Entomology, Quy Nhon, Vietnam

<sup>4</sup>National Institute of Malariology, Parasitology and Entomology, Hanoi, Vietnam

<sup>5</sup>Centre for Malariology, Parasitology, and Entomology, Vientiane, Lao PDR

<sup>6</sup>National Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia

<sup>7</sup>Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR

<sup>8</sup>Institute of Research and Education Development, University of Health Sciences, Ministry of Health, Vientiane, Lao PDR

<sup>9</sup>Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK

<sup>10</sup>Wellcome Sanger Institute, Hinxton, UK

<sup>11</sup>The Open University, Milton Keynes, UK

## ABSTRACT

**Background:** Genetic surveillance of *Plasmodium falciparum* (*Pf*) is an important tool for tracking antimalarial resistant strains, informing decision-making by National Malaria Control Programmes (NMCPs). Here, we present an analysis of 5,754 samples collected by the GenRe-Mekong project, in collaboration with NMCPs in the Greater Mekong Subregion (GMS), powered by new user-friendly visualization tools developed to translate genomic data into accessible actionable information.

**Methods:** Samples collected from patients presenting at public health facilities between 2017 and 2022 were genotyped using the SpotMalaria platform. Output data included genotypes for markers of antimalarial resistance, and genetic barcodes for analysis of relatedness. We developed the grcMalaria R package, which allows users to specify sample selection criteria, and produce geographical maps of prevalence, diversity and relatedness. It also identifies circulating parasite clusters, characterizing their drug resistance profile and mapping their spread.

**Results:** Since 2020, a rapid reduction in *Pf* incidence was observed, alongside a decline of the KEL1/PLA1 lineage resistant to dihydroartemisinin-piperaquine (DHA-PPQ), previously dominant in the eastern GMS. The frequency of *plasmepsin2/3* amplifications, associated with piperaquine resistance, dropped from 62% in 2017-2019 to 2% in the first half of 2022. This coincided with a switch in frontline therapy, away from DHA-PPQ, in Cambodia, Thailand, and Vietnam. Artemisinin resistance levels remained high, with a regional prevalence of 89% in 2022. No evidence of emerging mefloquine resistance was found.

**Conclusion:** Routine genetic surveillance of *Pf* can reveal changes in parasite populations in response to public health interventions, especially when its results are translated into intuitive graphical visualizations, providing actionable information for NMCPs.

**Key words:** malaria, *Plasmodium falciparum*, drug resistance, genetic epidemiology, mapping, Greater Mekong Subregion.

## INTRODUCTION

*Plasmodium falciparum* (*Pf*), a causative agent of malaria, is responsible for more than 500,000 deaths per year, mainly in young African children [1]. Since the turn of the century, mortality has reduced, partly thanks to the availability of efficacious artemisinin-based combination therapies (ACTs), currently the first-line treatments in most endemic countries. However, parasites resistant to artemisinin and/or one of its ACT partner drugs have been reported in several regions, and have been circulating in the Greater Mekong Subregion (GMS) for over 15 years [2-8]. One of the tools used to counteract the spread of drug resistance is genetic surveillance [9, 10], which can be used to map molecular markers and conduct population-level analyses. Resulting information provides public health authorities with actionable knowledge that supports several malaria control and elimination use cases, such as selecting antimalarial drug policies, monitoring drug resistance, and responding to outbreaks [11].

One of the most critical priorities of National Malaria Control Programmes (NMCPs) in the GMS is to monitor and respond to population-level changes in antimalarial drug resistance. Since 2015, the spread of multidrug-resistant KEL1/PLA1 strains in the eastern GMS has led to widespread failures of dihydroartemisinin-piperazine (DHA-PPQ), then the frontline treatment in Cambodia, Thailand and Vietnam [12, 13]. As recommended by the WHO, NMCPs in these countries switched to alternative first-line ACTs once DHA-PPQ efficacy fell below the recommended threshold of 90% [14, 15]: Cambodia adopted a phased re-introduction of artesunate-mefloquine (AS-MQ) starting in 2014 [16-19], while five provinces of Vietnam and two provinces of north-eastern Thailand adopted artesunate-pyronaridine (AS-PYR) in 2020 [17-20]. Lao PDR (Laos) and Myanmar have continued the use of artemether-lumefantrine (AL), since its efficacy remained satisfactory [17, 19, 21]. The GenRe-Mekong project was established to conduct malaria genetic surveillance in partnership with NMCPs and local researchers in the GMS [9]. Parasitized dried blood spots (DBS) are collected from patients presenting at one of the dozens of partner public health facilities. Subsequently, DBS are processed using the SpotMalaria amplicon sequencing platform to extract Genetic Report Cards (GRC), which in turn are analysed at population level to produce reports that are returned to NMCPs. SpotMalaria targets specific genotypes associated with antimalarial resistance (Supplementary Table 1) [9], and profiles a set of polymorphisms- known as a genetic barcode- that capture genetic structure and diversity in *Pf* populations [9, 22-24]. To accelerate the integration of the resulting data into public health decision-making processes, NMCPs are supported with technical, genetic and domain knowledge, to assist with data interpretation. To this end, the GenRe-Mekong project develops informatics tools that help turn genomic data into meaningful graphical visualizations that support NMCP activities. The first of these tools, *grcMalaria*, is an R language package that produces geographical maps of malaria resistance

prevalence, diversity and relatedness, using GRCs as input. The tool is easy to use, requiring very few lines of coding, and return results rapidly, making geospatial analyses accessible to a wide range of users with different backgrounds.

We presented early results from the GenRe-Mekong project in a previous publication [9]. Here, we provide an update, describing changes in antimalarial drug resistance epidemiology in the GMS, based on an analysis of 5,754 *Pf* dried blood spot samples collected by GenRe-Mekong between 2017 and 2022 from symptomatic patients in Cambodia, Laos, and Vietnam, a time when several NMCPs changed their malaria treatment policies.

## METHODS

The procedures, operations and technical aspects of the GenRe-Mekong project were detailed in a previous publication [9]; here, we summarize the salient points in brief.

### Sample collection.

Samples were collected from symptomatic patients of all ages who had been confirmed positive for *Pf* by positive rapid diagnostic test or blood smear microscopy. Two or three 20 µL DBS were collected on filter paper by finger-prick, labelled with a unique identifier, and stored in plastic bags with silica gel before being shipped to the laboratories. In Laos, samples were collected in 5 provinces by the Center for Malariology, Parasitology, and Entomology (CMPE) and the Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU). In Vietnam, samples were collected from 11 provinces by the Institute of Malariology Parasitology and Entomology Quy Nhon (IMPE-QN), the National Institute of Malariology, Parasitology and Entomology (NIMPE) and the Oxford University Clinical Research Unit (OUCRU). In Cambodia, samples were collected in 5 provinces by the National Center for Parasitology, Entomology and Malaria Control (CNM) (Supplementary Table 2). Ethical approvals were obtained both from ethics committees in the country of collection, and from the Oxford Tropical Research Ethics Committee (OxTREC), as previously detailed [9].

### Sample genotyping

Parasite DNA was extracted from DBS samples and processed using the SpotMalaria v2 amplicon sequencing and genotyping platform as previously detailed [9]. Processing took place in partner laboratories at OUCRU, Ho Chi Minh City, Vietnam, or at the Wellcome Sanger Institute (WSI), Hinxton, UK. Parasite species were confirmed either by testing mitochondrial sequences for species-specific alleles, by ascertaining the presence of *Pf* genotypes in the genetic barcode, or by additional quantitative polymerase chain reaction (qPCR). Amplifications of the *Pf* genes *multidrug resistance 1 transporter (mdr1)* and *plasmepsin 2/3 (pm23)* were also detected by additional qPCR (Supplementary

Table 1). Genotyping, data processing, and informatics support was provided by WSI. The resulting GRC data are a standardized set of genotypes associated with resistance to several antimalarials, as well as a 101-SNP barcode, with positions selected based on their ability to differentiate populations and their power to recapitulate genetic distance [9]. The generated genotypes were used to predict resistance to clinically relevant antimalarials, based on a published set of rules [9].

### **Data analysis and visualisation**

To analyze and visualise data from the GRC, we used the `grcMalaria` package (version 2.0.0) installed on R (version 4.2.3) [25]. The GRC format requires structured geographical data, which is achieved by linking study locations to administrative divisions from GADM (Database of Global Administrative Areas) [26], a global catalogue of administrative divisions. Geographical structuring supports the aggregation of data at different levels of geographical granularity. In the analyses presented here, we aggregated samples at provincial level (AdminDiv1).

To analyze changes in *Pf* populations over time, we divided the samples into three periods (2017-2019, 2020-2021, 2022). The sample distribution was visualised using the `grcMalaria mapSampleCounts` function. To calculate the frequency of parasites resistant to a given antimalarial, we used the function `mapDrugResistancePrevalence`, which estimates the proportion of resistant parasites by dividing the number of resistant samples by the sum of resistant and sensitive samples, disregarding samples whose drug-resistant status could not be determined. Pie charts, representing the allele proportion of drug-resistant markers in a given administrative division, were generated using `mapAlleleProportions`. Additional graphs were produced either by Microsoft Excel or by the R `ggplot2` (version 3.5.1) library [28]; error bars representing 95% confidence intervals were calculated using Wilson Interval with corrections (BinomCI; DescTools R package version 0.99.54) [27].

### **Analysis of highly related parasites**

To identify clusters of highly related parasites, we applied the `grcMalaria findClusters` function, setting a genetic similarity threshold of 95% with at least 20 members in each cluster. At this level of similarity, clusters of parasites with essentially identical genetic barcodes are identified, allowing for low levels of error introduced by sequencing. To minimize the influence of missingness in genetic distance estimations, we only included 'high quality' samples (<25% barcode genotype missingness) and applied imputation (`impute=TRUE`) to positions called as 'missing' [9]. To assign sample set into clusters, we applied a community detection algorithm to a network constructed from pairwise distances computed by comparing genetic barcodes between sample pairs. The proportion of most prevalent clusters were visualized as pie charts, generated using the `mapClusterSharing` function.

## Data availability

This paper uses a subset of GenRe-Mekong data, which includes all samples collected by the project during routine surveillance in the eastern GMS. The GenRe-Mekong project has made all genetic data openly available at <https://github.com/GenRe-Mekong/Data>, including: the full GenRe-Mekong dataset, containing 13,535 samples from eight countries; a subset that includes 5,754 *Pf* samples from the present analysis; and a global dataset derived from the whole-genome data from samples in the MalariaGEN Pf7 data resource [29]. The datasets are accompanied by information on the GRC format, and a data dictionary for converting third-party data into GRC format. Links to source code for the *grcMalaria* R package can be found at <https://github.com/malariagen/grcMalaria>.

A comprehensive guide detailing the functions of the *grcMalaria* package is available at <https://genremekong.org/tools/grcmalaria-r-package-user-guide>.

## Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

## RESULTS

Between January 2017 and June 2022, GenRe-Mekong collected and processed a total of 5,754 *Pf* samples from 21 provinces in three countries (Figure 1B, Supplementary Figure 1). In Vietnam, the project processed 3,201 patient samples of malaria in 2017-2022 (32.6% of WHO-reported *Pf* infections); in the Laos, it processed 2,371 samples over the same period (16.1%); while in Cambodia, collections took place between July 2020 and June 2022, producing 182 samples (14.3% of the WHO-reported infections in the country) (Supplementary Figure 2) [30-32]. Around 2020, a rapid decrease in *Pf* incidence took place in all three countries (Figure 1A), as confirmed by data reported to WHO [17]. Laos showed the first signs of decline in sample numbers in 2019, followed by Vietnam the following year (Figure 1A). As incidence declined over time, *Pf* populations became more geographically isolated. By 2022, the majority of samples were concentrated in one province in each country: Attapeu in Laos, Gia Lai in Vietnam, and Pursat in Cambodia (Figure 1B & Supplementary Table 2); these provinces had consistently exhibited the highest incidence within their respective countries in previous years.

## DHA-PPQ resistance decline after changes in first-line treatments

In the 2017-2019 period, 62% (1,957/3,132) of all collected samples were predicted to be resistant to DHA-PPQ (Figure 2A). DHA-PPQ was used as frontline treatment for uncomplicated malaria in

Cambodia, Thailand and Vietnam prior to that period, which had led to the cross-border spread of the KEL1/PLA1 strain- resistant to both components of the DHA-PPQ ACT- across most of the eastern GMS [13]. Although KEL1/PLA1 began to diversify as it spread, it maintained its two characteristic haplotypes during this period: a *kelch13* C580Y mutant haplotype conferring artemisinin resistance, and a *pm23* amplification conferring resistance to piperazine. This strain also spread into southern Laos, likely as a spillover from neighboring countries, producing high levels of DHA-PPQ resistance in Attapeu and Champasak Provinces, despite the ACT not being used nationally. Starting in 2017, Cambodia gradually switched its frontline treatment from DHA-PPQ to AS-MQ [16-19], while Thailand and Vietnam switched from DHA-PPQ to other ACTs by 2020 [17-20]. Following these changes, regional DHA-PPQ predicted resistance fell steeply, to 30% (204/690) in 2020-2021, and 2% (2/81) in the first half year of 2022 (Figure 2A, Supplementary Figure 3A). To demonstrate that these changes in first-line treatment policies were the likely cause of DHA-PPQ resistance decline, we plotted the prevalence of predicted piperazine resistance (i.e. the *pm23* amplification prevalence), alongside the timeline of first-line treatment strategies for uncomplicated *Pf* in Vietnam (Figure 3). We observed that within 3 months after replacing DHA-PPQ with AS-PYR in 5 provinces, a reduction in *Pf* incidence and a decline in PPQ resistance began, which within 18 months led to the disappearance of piperazine-resistant parasites (Figure 3).

### **Resistance to other antimalarials**

Artemisinin resistance levels remained high throughout the period analyzed (Figure 2B & Supplementary Figure 3A), presumably because artemisinin-based combinations continued to be the first-line treatments in the region. However, in provinces at the border of the endemic region (Savannakhet in Laos, Quang Tri and Ninh Thuan in Vietnam), most parasites were predicted to remain susceptible to both artemisinin and piperazine throughout the study period (Figure 2B), suggesting that the local parasite populations were isolated from the spreading resistant strains in the eastern GMS. Predicted mefloquine resistance remained low in the region across the study periods (Supplementary Figure 3A, Supplementary Figure 4), even after Cambodia adopted AS-MQ as frontline therapy in 2017 [16]; in 2022, we detected no samples carrying an *mdr1* amplification, a marker associated with mefloquine resistance [33]. Markers of resistance to chloroquine, sulfadoxine, and pyrimethamine remained high across the region throughout the study period (Supplementary Figure 3, Supplementary Figure 5).

### **Distribution of *kelch13* allele variants across fragmented populations**

It has been shown that artemisinin-resistant strains in the eastern GMS originated from multiple founder populations carrying different *kelch13* alleles [34]. Maps of *kelch13* allele variant proportions

suggest that strains carrying different variants persisted [35], even though their geographical distribution and prevalence changed over time (Figure 4). In 2017-2019, the majority of the artemisinin-resistant parasites carried the *kelch13* C580Y mutation (98%, 2,482/2,539), and 79% of these mutants (1,957/2,482) were classified as KEL1/PLA1 (possessing both *kelch13* C580Y and *pm23* amplification) (Supplementary Figure 6). However, since 2020 the dominance of KEL1/PLA1 waned, and other *kelch13* variants, previously circulating at low frequency, expanded in the region. In the western provinces of Cambodia, *kelch13* Y493H increased in frequency, and eventually dominated the population in Pursat province in 2022 (Figure 4, Supplementary Table 3). In Laos, *kelch13* R539T expanded in 2020-2021 in Attapeu and Champasak provinces, causing an outbreak [35]. It subsequently subsided in 2022, as parasites possessing the *kelch13* C580Y mutation but no *pm23* amplification increased in Attapeu. In Vietnam, C580Y remained the dominant *kelch13* variant.

### Clustering of parasite populations

Expecting the changes in *kelch13* allele distributions to be a result of change in prevalence of circulating populations, we sought to examine population structure by clustering *Pf* barcodes and examining the geographical distributions of the clusters. Clustering identical or near-identical parasites (sharing at least 95% barcode similarity) identified 25 clusters (Table 1). During 2017-2019, four out of the five largest clusters (labelled KLV-01, KLV-02, KLV-03, KLV-05) were diverging groups emerging from the KEL1/PLA1 strain, which at that point accounted for 42% (1,957/4,632) of samples; some of these large clusters (e.g. KLV-01, KLV-05) had considerable geographic spread across the eastern GMS (Figure 5). Following the implementation of new front-line treatment policies, however, a noticeable shift in population dynamics occurred. From 2020, clusters remained contained within single countries, and often within single provinces. Additionally, populations of non-KEL1/PLA1 clusters began to expand reaching high frequencies, e. g. KLV-04 and KLV-08 in southern Laos, and KLV-22 in western Cambodia (Figure 5, Table 1). In Vietnam, the KEL1/PLA1-derived clusters KLV-01 and KLV-03 continued to circulate but lost their *pm23* amplification (Supplementary Table 4). By the second quarter of 2021, none of the circulating clusters possessed the *pm23* amplification, and the Central Highlands of Vietnam were dominated by the piperaquine-susceptible KLV-03 population (Figure 5). Taken together, these results suggest that the observed reduction in DHA-PPQ resistance in 2020-2021 can be explained by the disappearance of KEL1/PLA1 clusters, and their loss of *pm23* amplification, occurring after changes in first-line treatment policies.

### Use of grcMalaria for non-GMS data

The above analyses were conducted using the grcMalaria library, a new software tool for mapping GRC-formatted data. To demonstrate that its capability is not limited to analyzing GMS surveillance



data, we created a GRC dataset from the MalariaGEN Pf7 global whole-genome sequencing data resource, which comprises 20,831 samples from 33 countries [29]. As an example of grcMalaria usage, we generated maps of chloroquine resistance and *mdr1* haplotypes across different geographical regions (Supplementary Figure 7). The software tools and Pf7 dataset are freely available from the GenRe-Mekong website (see Methods).

## DISCUSSION

In this study we analysed the genetic epidemiology of *Pf* in the eastern GMS through longitudinal surveillance between 2017 and 2022, updating our previously published results up to 2019 [9]. Our data shows that dramatic epidemiological changes occurred following changes in first-line treatment policies in the region. Amongst these changes, it is worth highlighting a marked decline in *Pf* infections, the near disappearance of *pm23* amplifications from circulating strains, the fragmentation of the artemisinin-resistant populations, and the absence of *mdr1* amplifications that would otherwise threaten AS-MQ treatment efficacy.

The prevalence of DHA-PPQ resistant parasites collapsed from 62% in 2017-2019 to 2% in 2022, the timing coinciding with the adoption of new first-line treatment strategies in three countries in the eastern GMS. In the previous decade, the prolonged use of DHA-PPQ as frontline treatment resulted in massive selective pressure on the parasites, and a rapid spread of KEL1/PLA1 co-lineages across the eastern GMS once they emerged [12, 13, 36, 37]. The parasite population responded just as strikingly and rapidly to the release of pressure from changes in treatment guidelines as it did to the intense DHA-PPQ pressure from public health policies. It is likely that, in the absence of piperazine pressure, *pm23* amplifications are costly in terms of parasite fitness, and lead to a survival disadvantage in the absence of piperazine pressure. A recent *in vitro* study supported this notion by demonstrating that cultured C580Y parasites spontaneously de-amplify *pm23* when piperazine pressure is removed [38]. Thus, the change in policy appears to have produced two effects on KEL1/PLA1 parasites: either caused them to succumb in competition with fitter artemisinin-resistant strains, which had been circulating at low frequency during KEL1/PLA1 dominance [35]; or cause them to de-amplify *pm23*, improving their fitness in the new environment. At the same time, the timeline of events also strongly suggests that the introduction of efficacious replacements for DHA-PPQ is at least partially responsible for the sudden collapse in the overall number of samples [16, 17, 20, 21], although it is hard to tease apart the contribution of other co-occurring factors, such as restriction of mobility due to the COVID-19 pandemic.

Reassuringly, we detected very few samples with predicted resistance to mefloquine, and none in Cambodia where this drug is now used as part of the first-line ACT. On multiple occasions since the 1990s, the use of mefloquine, either as a stand-alone drug or as part of an ACT, has intermittently led to reduced treatment efficacy in the GMS, due to the emergence of parasites possessing *mdr1* amplifications [39]. However, between 2019 and 2021 we found only 9 isolates with *mdr1* amplifications, all in the province of Attapeu in Laos; seven of these belonged to the *kelch13* R539T strain responsible for a *Pf* outbreak in 2021 [35].

Although we can predict resistance for a broad range of antimalarials, a limitation to the current study is the lack of validated genetic markers of resistance to a number of ACT partner drugs, including lumefantrine, used in Myanmar and Laos, and pyronaridine, used in Thailand and Vietnam. Pyronaridine is a relatively new drug, used only as a partner drug, for which no resistance has been demonstrated to date; a recent meta-analysis of 5,711 patients found that failure rates remain below 5% [40]. Lumefantrine, on the other hand, is a widely used drug in oral co-formulations, used with artemether as first-line treatment in most African countries, and therefore exerting significant selective pressure onto the parasite population globally. While some studies have described a potential phenotypic effect on lumefantrine of *mdr1* variants, evidence is not strong, and confirmatory genome-wide association studies (GWAS) have not yet been performed. Furthermore, studies have not been able to relate *mdr1*-induced reductions of *in vitro* susceptibility to *in vivo* clinical outcomes [41, 42]. To complicate matters further, food intake may influence lumefantrine bioavailability, due to its lipophilic nature, which could partially explain the reduced efficacy sometimes observed in the field [43]. Further research, such as a highly statistically powered GWAS, is urgently needed to identify markers that can track resistance to these drugs. This has become particularly important in view of the recent emergence of artemisinin-resistant parasites in eastern Africa [44].

We have shown that systematic and ongoing sampling by routine surveillance, combined with extensive site coverage, is informative for the detection of epidemiological changes and for comparisons of prevalence between regions over time. Additionally, results were produced more efficiently than in traditionally performed therapeutic efficacy studies, lowering costs, while increasing actionability due to reduced turn-around times between data collection and reporting of results. As the GMS moves closer to elimination, and the number of patients infected with *Pf* dwindle, the continuation of longitudinal surveillance continues to be very important, since parasite populations change rapidly, and more agile interventions are needed. At the same time, planning of genetic surveillance efforts becomes increasingly challenging, due to increased uncertainty and low predictability. In practice this influences the ability to collect samples, as well as increased time to

accumulate enough samples needed for batch -shipping, and -sequencing. In this new epidemiological scenario, genetic surveillance efforts will have to address different use cases, such as outbreak analyses and importations of foreign malaria infections [11]. Furthermore, as the incidence of *Pf* diminishes, NMCPs will have to contend with rising numbers of patients infected with other *Plasmodium* species, notably *P. vivax*, but also *P. malariae* and *P. knowlesi*, which are currently neglected and for which to date no genetic surveillance tools are available. GenRe-Mekong is committed to supporting NMCPs in the GMS with genetic surveillance tools for *P. vivax*, currently under development.

One of the key challenges of genetic epidemiology is that of translating genetic data into actionable knowledge relevant to NMCP activities [11]. Our data is only useful if it provides value to public health bodies engaged in malaria control and elimination; one of the first lessons learnt while implementing the GenRe-Mekong project is that genotypes, mutations and haplotypes have little value without an understandable context in which they can be assessed. Even derivative and aggregate data, such as the prevalence of a mutation associated with resistance, are not useful to NMCP experts unless accompanied by other data points that show spatial or temporal trends. We developed the grcMalaria software library with the aim of increasing the accessibility of genetic epidemiology analysis in daily practice, by simplifying and reducing time needed for analyses tasks. This freely available tool focuses on mapping, using administrative divisions that are meaningful to NMCPs, and supporting flexible selection of samples and division of the dataset into time slices, which produce parallel maps for comparison. Furthermore, the tool supports the aggregation of multiple GRC datasets, encouraging regional analyses of cross-border flow, and data sharing. The library incorporated clustering algorithms that can group samples by similarity and map the geographical distribution of the clusters obtained; this allows users to distinguish, for example, strains that circulate locally in a district from those spreading across borders.

The results presented in this study emphasize the importance of regional strategies for selection of treatment policies to mitigate the spread of antimalarial drug resistance, and stresses the value of different first-line treatment regimens among neighboring countries. For future malaria elimination efforts, it will be paramount to continue genetic surveillance in the final phases of elimination so the experience of the GMS can inform strategic planning for other regions approaching elimination.


## TABLES AND FIGURES

**Table 1. Temporal cluster distribution of *P. falciparum* samples with corresponding genotype.** For each cluster, we show: the cluster label; name from previous studies; proportion of samples per year of collection; proportion of samples predicted resistant to artemisinin (ART), piperaquine (PPQ), and mefloquine (MQ); chloroquine (CQ), sulfadoxine (SX) and pyrimethamine (PM); main *kelch13* variant identified in the cluster; whether the cluster is a KEL1/PLA1 haplotype. Clusters of at least 20 members were formed using Louvain community detection algorithm to assign samples sharing at least 95% of the genetic barcode into groups. Samples that could not be assigned to a cluster with these parameters were labelled as ‘not clustered’.


Cluster	Previous names	Proportion of samples in each year						Resistant to						Main <i>kelch13</i>	KEL1/PLA1
		2017	2018	2019	2020	2021	2022	ART	PPQ	MQ	CQ	SX	PM		
KLV-01		6%	8%	21%	16%	4%	100%	89%	0%	100%	100%	100%	C580Y	Yes	
KLV-02		1%	12%	18%	4%		100%	98%	0%	100%	100%	100%	C580Y	Yes	
KLV-03		0%	1%	13%	10%	16%	13%	100%	69%	0%	100%	100%	100%	C580Y	Yes
KLV-04	LAA1 <sup>a</sup>	0.2%	0.5%	0.3%	18%	15%	1%	100%	0%	14%	100%	100%	100%	R539T	
KLV-05		4%	4%	3%	3%	0.5%		100%	78%	0%	100%	100%	100%	C580Y	Yes
KLV-06		5%	3%	1%	1%			6%	1%	0%	100%	0%	100%	WT	
KLV-07		5%	2%	0.1%				100%	85%	0%	100%	100%	100%	C580Y	Yes
KLV-08	LAA2 <sup>a</sup> ; KH2 <sup>b</sup>	1%	1%	0.2%	4%	10%	22%	99%	2%	0%	100%	100%	100%	C580Y	
KLV-09		1%	1%	3%	3%			100%	100%	0%	100%	100%	100%	C580Y	Yes
KLV-10		3%	2%	0.5%	0.2%			1%	0%	0%	100%	0%	100%	WT	
KLV-11				0.1%		14%		0%	0%	0%	0%	0%	100%	WT	
KLV-12		2%	1%	1%				0%	2%	0%	100%	100%	100%	WT	
KLV-13		0.3%	1%	2%	1%			100%	85%	0%	100%	100%	100%	C580Y	Yes
KLV-14			2%	0.3%	0.2%			0%	0%	0%	100%	100%	100%	WT	
KLV-15		1%	1%			0.2%		8%	0%	0%	100%	0%	100%	WT	
KLV-16			1%	0.2%	3%			0%	0%	0%	100%	0%	100%	WT	
KLV-17		2%	1%	0.1%				100%	97%	0%	100%	100%	100%	C580Y	Yes
KLV-18			1%		0.2%			0%	0%	0%	100%	0%	100%	WT	
KLV-19		0.4%	1%	0.5%				0%	0%	0%	100%	0%	100%	WT	
KLV-20			1%	0.2%				0%	0%	0%	100%	100%	100%	WT	
KLV-21		1%	0.5%	1%				0%	0%	0%	100%	100%	100%	WT	
KLV-22					1%	4%	3%	100%	0%	0%	100%	100%	100%	C580Y	
KLV-23		1%	1%					100%	100%	0%	100%	100%	100%	C580Y	Yes
KLV-24		1%	1%	0.1%				75%	0%	0%	100%	100%	100%	C580Y	
KLV-25		0.3%	0.1%	0.5%	1%			100%	94%	0%	100%	100%	100%	C580Y	Yes
Not clustered		67%	55%	33%	35%	35%	61%								
Total samples		1291	1894	1447	608	413	101								

<sup>a</sup> Wasakul, Disratthakit [35]


<sup>b</sup> Miotto, Almagro-Garcia [45]




**Figure 1. Genotyped *P. falciparum* (*Pf*) samples collected by the GenRe-Mekong project in collaboration with National Malaria Control Programmes (NMCPs). A) Sample distribution from January 2017 to June 2022. Brackets show NMCP names. No samples were collected in Cambodia as part of routine surveillance in 2018 and 2019. B) Sample distribution by province in 2020-2021 and 2022. Colour corresponds to country. CNM: National Center for Parasitology, Entomology and Malaria Control (Cambodia), CMPE: Center for Malariology, Parasitology, and Entomology (Laos), IMPEQN: Institute of Malariology Parasitology and Entomology Quy Nhon (Vietnam), NIMPE: National Institute of Malariology, Parasitology and Entomology (Vietnam).**



**Figure 2. Predicted resistance to A) dihydroartemisinin-piperaquine (DHA-PPQ) and B) artemisinin at provincial level. Left: 2017-2019, middle: 2020-2021, right: January – June 2022. Resistance was predicted based on a published set of phenotype rules [9]. Colour reflects resistance prevalence ranging from 0 to 1, where 0 means no parasites show resistance and 1 means 100% of the parasites in the province carried the resistance markers thus predicted to be resistant to the drug. A marker appears when there are at least 2 samples from the province.**




**Figure 3. Predicted level of piperavaquine resistance and first-line policy in Vietnam.** Bar chart shows number of samples with wild-type (WT) and *plasmepsin2/3* gene amplification (left axis), against proportion of piperavaquine resistance (PPQ-R) in Vietnam (right axis). Purple shaded area shows 95% confidence interval. Data is aggregated by quarter Q1: January – March; Q2: April – June; Q3: July – September; Q4: October – December. Grey bar underneath the graph shows first-line treatment policy of *P. falciparum* in Vietnam, dihydroartemisinin-piperavaquine (DHA-PPQ) and pyronaridine-artesunate (AS-PYR). \*AS-PYR was adopted in 5 endemic provinces in 2020 (Binh Phuoc, Dak Nong, Gia Lai, Dak Lak, and Phu Yen).



**Figure 4. Prevalence of *kelch13* alleles between 2017 and 2022.** Pie chart shows proportion of *kelch13* alleles in each province where samples had been collected. Size of pie chart corresponds to the sample number in the province. A wild-type (WT) parasite is predicted to be sensitive to artemisinin, all but two of the *kelch13* alleles detected between 2017 and June 2022 are associated with delayed parasite clearance thus predicted to be resistant to artemisinin. The two rare alleles, G357S (*kelch13* BTB/POZ domain) and G544R (*kelch13* propeller domain), are not in World Health Organization’s validated marker list, thus their associations with artemisinin resistance are undetermined.





**Figure 3. Proportion of most prevalent *P. falciparum* clusters in each province across three periods.** Left: 2017-2019, middle: 2020-2021, right: January – June 2022. Clusters were identified using community detection algorithm to assign highly related parasites sharing at least 95% genetic barcode similarity (near-identical parasites) into clusters of at least 20 members, resulting in 25 clusters. In 2017-2019, 24 clusters were present, while 17 clusters were present in 2020-2021 and four clusters were present in 2022. To improve visualization, colours are only given to the top five clusters in each year. Grey colour represents other clusters. White segments represent proportion of samples that did not form a cluster at the specified thresholds. In the legend, clusters are arranged in descending order of cluster size. Main *kelch13* variant identified in the cluster and *plasmepsin2/3* amplification (p+) are shown in brackets following the cluster name. The size of pie-charts is proportional to the sample size for the province.

## **ACKNOWLEDGEMENTS**

This study was funded by the Bill & Melinda Gates Foundation and by The Global Fund to Fight AIDS, Tuberculosis and Malaria. This research was funded in part by the Wellcome Trust. The authors wish to thank all the patients and guardians who generously agreed to provide blood samples. We wish to thank all public health and medical staff who participated in the collection of samples. Genome sequencing and genotyping was performed by the WSI and OUCRU, and sequencing data processing was supported by the MalariaGEN Resource Centre. We thank the staff of the WSI Sample Logistics, Sequencing, and Informatics facilities for their contribution; Eleanor Drury for support in the sample processing pipeline.

## REFERENCES

1. WHO. World malaria report 2022. Geneva: World Health Organization, 2022.
2. Denis, M.B., et al. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. *Trop Med Int Health*. **11**, 1800-7 (2006).
3. Denis, M.B., et al. Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. *Trop Med Int Health*. **11**, 1360-6 (2006).
4. van der Pluijm, R.W., et al. Determinants of dihydroartemisinin-piperaquine treatment failure in *Plasmodium falciparum* malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. *Lancet Infect Dis*. **19**, 952-61 (2019).
5. Mairet-Khedim, M., et al. Clinical and *In Vitro* resistance of *Plasmodium falciparum* to artesunate-amodiaquine in Cambodia. *Clin Infect Dis*. **73**, 406-13 (2021).
6. Plucinski, M.M., et al. Efficacy of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for treatment of uncomplicated *Plasmodium falciparum* malaria in Angola, 2015. *Malar J*. **16**, 62 (2017).
7. Tumwebaze, P.K., et al. Decreased susceptibility of *Plasmodium falciparum* to both dihydroartemisinin and lumefantrine in northern Uganda. *Nat Commun*. **13**, 6353 (2022).
8. Dondorp, A.M., et al., Artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med*. **5**, 455-67 (2009).
9. Jacob, C.G., et al. Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination. *eLife*. **10**, e62997 (2021).
10. Mayor, A., et al. Prospective surveillance study to detect antimalarial drug resistance, gene deletions of diagnostic relevance and genetic diversity of *Plasmodium falciparum* in Mozambique: protocol. *BMJ Open*. **12**, e063456 (2022).
11. Miotto, O. Genetic epidemiology use cases for malaria control programmes: a methodology [Internet]. Bangkok; 2023 [updated 2023, cited 2024 March 19] Available from: <https://www.malariagen.net/resources/use-cases-for-nmcps/>.
12. Amato, R., et al. Genetic markers associated with dihydroartemisinin-piperaquine failure in *Plasmodium falciparum* malaria in Cambodia: a genotype-phenotype association study. *Lancet Infect Dis*. **17**, 164-73 (2017).
13. Hamilton, W.L., et al. Evolution and expansion of multidrug-resistant malaria in southeast Asia: a Genetic epidemiology study. *Lancet Infect Dis*. **19**, 943-51 (2019).
14. WHO. Guidelines for the treatment of malaria, 3rd edition. Geneva: World Health Organization, 2015.
15. Amaratunga, C., et al. Dihydroartemisinin-piperaquine resistance in *Plasmodium falciparum* malaria in Cambodia: a multisite prospective cohort study. *Lancet Infect Dis*. **16**, 357-65 (2016).
16. CNM. National Center for parasitology, entomology and malaria control: national malaria programme review 2019. Phnom Penh: National Center for parasitology, entomology and malaria control: 2019.

17. WHO. Accelerating malaria elimination in the Greater Mekong. Geneva: World Health Organization, 2022.
18. Peto, T.J., et al. Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. *Lancet Infect Dis.* **22**, 867-78 (2022).
19. Imwong, M., et al. Evolution of multidrug resistance in *Plasmodium falciparum*: a longitudinal study of genetic resistance markers in the Greater Mekong Subregion. *Antimicrob Agents Chemother.* **65**, e0112121 (2021).
20. Sudathip, P., et al. Progress and challenges of integrated drug efficacy surveillance for uncomplicated malaria in Thailand. *Malar J.* **20**, 261 (2021).
21. Simmalavong, N., et al. Expanding malaria diagnosis and treatment in Lao PDR: lessons learned from a public-private mix initiative. *Malar J.* **16**, 460 (2017).
22. Daniels, R.F., et al. Modeling malaria Genetics reveals transmission decline and rebound in Senegal. *Proc Natl Acad Sci U S A.* **112**, 7067-72 (2015).
23. Wong, W., et al.  $R_H$ : a genetic metric for measuring intrahost *Plasmodium falciparum* relatedness and distinguishing cotransmission from superinfection. *PNAS Nexus.* **1**, pgac187 (2022).
24. Kattenberg, J.H., et al. Novel highly-multiplexed AmpliSeq targeted assay for *Plasmodium vivax* genetic surveillance use cases at multiple geographical scales. *Front Cell Infect Microbiol.* **12**, 953187 (2022).
25. R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.
26. GADM. GADM database of Global Administrative Areas, version 2.0. [Internet]. Berkeley: Global Administrative Areas; 2012 [updated 2012, cited 2024 March 18] Available from: [www.gadm.org](http://www.gadm.org).
27. Signorell, A. (2024). DescTools: Tools for Descriptive Statistics. R package version 0.99.54, <https://andrisignorell.github.io/DescTools/>.
28. Wickham, H. (2016). ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York. ISBN 978-3-319-24277-4, <https://ggplot2.tidyverse.org>.
29. MalariaGEN, et al. Pf7: an open dataset of *Plasmodium falciparum* genome variation in 20,000 worldwide samples. *Wellcome Open Res.* **8**, 22 (2023).
30. WHO. Mekong malaria elimination: epidemiology summary, volume 4, October-December 2018. Geneva: World Health Organization, 2018. WHO reference number: WHO/CDS/GMP/MME/2018.05.
31. WHO. Mekong malaria elimination: epidemiology summary, volume 12, October-December 2020. Geneva: World Health Organization, 2020. WHO reference number: WHO/UCN/GMP/MME/2020.06.
32. WHO. Mekong Malaria Elimination: epidemiology summary, volume 16, October-December 2021. Geneva: World Health Organization, 2022. WHO reference number: WHO/UCN/GMP/MME/2022.02.
33. Price, R.N., et al. Mefloquine resistance in *Plasmodium falciparum* and increased *pfmdr1* gene copy number. *Lancet.* **364**, 438-47 (2004).

34. Miotto, O., et al. Genetic architecture of artemisinin-resistant *Plasmodium falciparum*. *Nat Genet.* **47**, 226-34 (2015).
35. Wasakul, V., et al. Malaria outbreak in Laos driven by a selective sweep for *Plasmodium falciparum* *kelch13* R539T mutants: a genetic epidemiology analysis. *Lancet Infect Dis.* **5**, 568-77 (2023).
36. Imwong, M., et al. Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. *Lancet Infect Dis.* **20**, 1470-80 (2020).
37. Imwong, M., et al. The spread of artemisinin-resistant *Plasmodium falciparum* in the Greater Mekong subregion: a molecular epidemiology observational study. *Lancet Infect Dis.* **17**, 491-7 (2017).
38. Mok, S., et al. Mapping the Genetic landscape of multidrug resistance in *Plasmodium falciparum* and its impact on parasite fitness. *Sci Adv* 2023. **9**, eadi2364 (2023).
39. Lek, D., et al. Efficacy of three anti-malarial regimens for uncomplicated *Plasmodium falciparum* malaria in Cambodia, 2009-2011: a randomized controlled trial and brief review. *Malar J.* **21**, 259 (2022).
40. Pryce, J., Taylor, M., Fox, T., Hine, P. Pyronaridine-artesunate for treating uncomplicated *Plasmodium falciparum* malaria. *Cochrane Database Syst Rev.* **6**, CD006404 (2022).
41. Lim, P., et al. *Pfmdr1* copy number and artemisinin derivatives combination therapy failure in falciparum malaria in Cambodia. *Malar J.* **8**, 11 (2009).
42. Baraka, V., et al. Impact of treatment and re-treatment with artemether-lumefantrine and artesunate-amodiaquine on selection of *Plasmodium falciparum* multidrug resistance gene-1 polymorphisms in the Democratic Republic of Congo and Uganda. *PLoS One.* **13**, e0191922 (2018).
43. Ashley, E.A., et al. How much fat is necessary to optimize lumefantrine oral bioavailability? *Trop Med Int Health.* **12**, 195-200 (2007).
44. Rosenthal, P.J., et al. The emergence of artemisinin partial resistance in Africa: how do we respond? *Lancet Infect Dis.* Epub ahead of print (2024).
45. Miotto, O., et al. Multiple populations of artemisinin-resistant *Plasmodium falciparum* in Cambodia. *Nat Genet.* **45**, 648-55 (2013).